Merck
  • Home
  • Search Results
  • Microwave ablation of lung tumours: single-centre preliminary experience.

Microwave ablation of lung tumours: single-centre preliminary experience.

La Radiologia medica (2013-11-16)
Gianpaolo Carrafiello, Monica Mangini, Federico Fontana, Anna Maria Ierardi, Giuseppe De Marchi, Nicola Rotolo, Claudio Chini, Salvatore Cuffari, Carlo Fugazzola
ABSTRACT

This study was done to evaluate the feasibility, effectiveness and safety of microwave (MW) ablation of lung tumours. Twenty-four patients underwent percutaneous MW ablation of 26 intraparenchymal pulmonary masses. All patients were judged to be inoperable on the basis of tumour stage, comorbidities, advanced age and/or refusal to undergo surgery. Ablation was performed using a microwave generator (Evident Microwave Ablation System, Covidien Ltd., Dublin). Lesions with a diameter ≤ 3 cm were treated with a single antenna, lesions with a diameter >3 cm were treated by positioning two or more antennae, simultaneously. All patients underwent computed tomography (CT) follow-up with and without contrast administration at 1, 3 and 6 months and then yearly in combination with complete blood and metabolic tests. Technical success was 100 %. No major complications were recorded. Asymptomatic grade-1 pneumothorax was recorded in 9 patients (37.5 %). One case of asymptomatic pleural effusion and one of haemoptysis, not requiring transfusion, were observed. No patients were diagnosed with a post-ablation syndrome. Complete necrosis was observed in 16 of 26 lesions (61.6 %). Partial necrosis was obtained in 30.8 % (8/26 lesions); in one case (3.8 %) a progression of the disease was recorded and in another case (3.8 %) a stability was observed. Our preliminary experience may be considered in accordance with literature dates, in terms of efficacy and safety.

MATERIALS
Product Number
Brand
Product Description

碘克沙醇, European Pharmacopoeia (EP) Reference Standard